Market Research Logo

Global Acromegaly and Gigantism Drugs Market 2018-2022

Global Acromegaly and Gigantism Drugs Market 2018-2022

About Acromegaly and Gigantism Drugs

The acromegaly and gigantism are GH-related diseases. Acromegaly disease occurs in adults while gigantism occurs in children.

Technavio’s analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA


Technavio's report, Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Ipsen
  • Novartis
  • Pfizer
Market driver
  • Strong pipeline
  • For a full, detailed list, view our report
Market challenge
  • Difficulty in diagnosis
  • For a full, detailed list, view our report
Market trend
  • Growing popularity of drugs over surgeries
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Acromegaly and Gigantism Drugs Market 2018-2022

Technavio recognizes the following companies as the key players in the global acromegaly and gigantism drugs market: Ipsen, Novartis, and Pfizer

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is growing popularity of drugs over surgeries. Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis. The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries. For instance, as per the NIH, in a study involving total 62 subjects, 31 subjects were treated by transsphenoidal surgery, and four subjects were cured. Out of these 31 subjects treated with transsphenoidal surgery, post-operative anterior pituitary hormone deficiency was seen in 10 subjects, and diabetes insipidus got developed in one subject.”

According to the report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth. Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition. For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.

Further, the report states that one of the major factors hindering the growth of this market is Difficulty in diagnosis. In the last two decades, numerous important advancements took place in the domain such as the emergence of assays with improved sensitivity for IGF-1 and GH, development of automated software for evaluating physical changes associated with the disease, and widespread pituitary examination using magnetic resonance imaging (MRI). Despite all these advancements, acromegaly remains clinically under-diagnosed.

Companies Mentioned

Ipsen, Novartis, and Pfizer

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global acromegaly and gigantism drugs market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast 2017-2022
      • Table Global acromegaly and gigantism drugs market 2017-2022 ($ mn)
      • Table Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2017
  • Pipeline analysis
    • Table Pipeline landscape by development phase
    • Table Key clinical trials for global acromegaly and gigantism drugs market
  • Market segmentation by drug class
    • Segmentation by drug class
      • Table Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%)
    • Comparison by drug class
      • Table Comparison by drug class
    • Somatostatin analogs - Market size and forecast 2017-2022
      • Table Somatostatin analogs - Market size and forecast 2017-2022 ($ mn)
      • Table Somatostatin analogs - YoY growth 2018-2022 (%)
    • GH receptor antagonists - Market size and forecast 2017-2022
      • Table GH receptor antagonists - Market size and forecast 2017-2022 ($ mn)
      • Table GH receptor antagonists - YoY growth 2018-2022 (%)
    • Dopamine agonists - Market size and forecast 2017-2022
      • Table Dopamine agonists - Market size and forecast 2017-2022 ($ mn)
      • Table Dopamine agonists - YoY growth 2018-2022 (%)
    • Recombinant human IGF-1 - Market size and forecast 2017-2022
      • Table Recombinant human IGF-1 - Market size and forecast 2017-2022 ($ mn)
      • Table Recombinant human IGF-1 - YoY growth 2018-2022 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • Americas - Market size and forecast 2017-2022
      • Table Americas - Market size and forecast 2017-2022 ($ mn)
      • Table Americas - YoY growth 2018-2022 (%)
      • Table Top three countries in Americas
    • EMEA - Market size and forecast 2017-2022
      • Table EMEA - Market size and forecast 2017-2022 ($ mn)
      • Table EMEA - YoY growth 2018-2022 (%)
      • Table Top three countries in EMEA
    • APAC - Market size and forecast 2017-2022
      • Table APAC - Market size and forecast 2017-2022 ($ mn)
      • Table APAC - YoY growth 2018-2022 (%)
      • Table Top three countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Percentage increase in GDI of India, China, and US for 2011-2016
    • Market challenges
  • Market trends
    • Growing popularity of drugs over surgeries
    • Focus on long-acting novel formulations
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Ipsen
      • Table Ipsen - Vendor overview
      • Table Ipsen - Business segments
      • Table Ipsen - Organizational developments
      • Table Ipsen - Geographic focus
      • Table Ipsen - Segment focus
      • Table Ipsen - Key offerings
      • Table Ipsen- Key customers
    • Novartis
      • Table Novartis - Vendor overview
      • Table Novartis - Business segments
      • Table Novartis - Organizational developments
      • Table Novartis - Geographic focus
      • Table Novartis - Segment focus
      • Table Novartis - Key offerings
    • Pfizer
      • Table Pfizer - Vendor overview
      • Table Pfizer - Business segments
      • Table Pfizer - Organizational developments
      • Table Pfizer - Geographic focus
      • Table Pfizer - Segment focus
      • Table Pfizer - Key offerings
      • Table Pfizer - Key customers
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report